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Background: Kidney injury molecule-1 (KIM-1) is expressed in tubular epithelial cells after injury and may have a
role in the development of renal graft fibrosis. In this study we evaluated the molecular and protein expressions of
KIM-1 in dysfunctional allografts and also mRNA KIM-1 expression in urine as potential biomarkers of graft fibrosis.
Methods: Protein and mRNA levels in renal tissue and urinary sediment cells of 69 kidney transplant recipients
that undertook for-cause graft biopsies were evaluated by immunohistochemistry and real-time polymerase chain
reaction. The histopathology was classified according to the 2007 Banff schema.
Results: KIM-1 protein expression was increased in biopsies with interstitial fibrosis and tubular atrophy (IF/TA)
compared with biopsies showing acute calcineurin inhibitor nephrotoxicity (CIN) (P <0.05). Kidney tissue KIM-1
mRNA signaling (in) was increased in biopsies with IF/TA compared with all other groups (P <0.05). In the urine cells
KIM-1 mRNA was also increased in patients with IF/TA compared with patients with acute CIN (P <0.05). Significant
correlations were found between KIM-1 protein and mRNA levels in tissue, between mRNA expressions in tissue
and urine and between protein tissue expression and gene expression in the urine.
Conclusions: KIM-1 seems to be a marker of kidney graft fibrosis. Urinary KIM-1 mRNA may become a useful
non-invasive biomarker of the injuries that can trigger intra-graft fibrotic processes, such as interstitial fibrosis and
tubular atrophy.
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In the last decades renal transplantation has become the
therapy of choice for many patients with end-stage renal
disease. Compared with chronic dialysis, kidney trans-
plantation offers longer survival and better quality of life
[1]. However, a variety of injuries to the allograft shortens
significantly transplant survival as demonstrated by cur-
rently observed half-lives, still much inferior then desired
[2]. These injuries lead to allograft fibrosis that is mainly* Correspondence: rmanfro@hcpa.ufrgs.br
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unless otherwise stated.caused by continuous alloimmune responses, drug toxic-
ities and viral infections [3]. Also, when the mechanism
leading to fibrosis can not be identified by histological
examination, the denomination interstitial fibrosis and
tubular atrophy is used in accordance with the Banff clas-
sification [4]. Usually the fibrosis driving process occurs
silently and is not perceived until the allograft starts to
loose function or a surveillance renal biopsy is performed.
KIM-1 (kidney injury molecule-1) is a type 1 trans-
membrane glycoprotein not detectable in normal kidney
tissue but inducible by ischemic and toxic insults. This
protein expresses in elevated amounts in the apical sur-
face of surviving proximal tubule epithelial cells and is
detectable in the urine [5]. Currently, the link between
acute injuries and fibrosis is poorly understood. Peritub-
ular capillary loss, a known consequence of acute injury,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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development of tubulointerstitial fibrosis [6]. It is conceiv-
able that clinical or subclinical aggressions to the renal
graft may trigger pro-fibrotic mechanisms which lead to
tissue fibrosis, and ultimately to loss of graft function. In
our previous studies we found that KIM-1 messenger
RNA, along with another fibrosis related molecules, to be
augmented in renal allografts with fibrosis [7,8].
In order to study this molecule as a non-invasive bio-
marker of undergoing fibrosis in renal grafts we evalu-
ated the molecular and protein expressions of KIM-1 in
the renal tissue of kidney allograft recipients and also
quantified its mRNA in urinary sediment cells (USC).
Methods
Patients
Sixty-nine kidney transplant recipients submitted to 81
indication graft biopsies were included. In all patients
immunosuppressive therapy was initiated before trans-
plantation and consisted of corticosteroids, sodium my-
cophenolate and calcineurin inhibitors. Twenty-four
patients received induction therapy with Basiliximab®
and six with Thymoglobulin®. Immunosuppressive ther-
apy was kept throughout the course of the transplant
and adjusted overtime according to our protocol, blood
levels of immunosuppressive drugs and the occurrence
of acute rejection, drug toxicities, infections and side
effects. Graft dysfunction was investigated for vascular,
urological, drug toxicity or infectious causes by Doppler
ultrasound, nuclear scans, calcineurin inhibitors blood
levels and urine cultures before the biopsies were per-
formed. For the biopsies two cores were obtained under
ultrasound guidance, using a 16G semi-automatic biopsy
gun. One third of the second obtained core was immedi-
ately frozen in liquid nitrogen and maintained at −70°C
for later RNA extraction. Slide evaluation was performed
by a kidney transplant pathologist unaware of the clin-
ical data. The Banff-2007 classification was used for the
histopathological diagnoses [4]. The final diagnosis for
each biopsy situation was established by evaluation of the
pathological criteria, clinical course, response to treat-
ments and outcomes. Patients and biopsies were then
classified into four major diagnostic groups: (a) acute
tubular necrosis (ATN; n = 9), acute rejection (AR; n = 43),
acute calcineurin inhibitor nephrotoxicity (CIN; n = 9)
and interstitial fibrosis and tubular atrophy (IF/TA;
n = 20). Six protocol biopsies obtained in stable recipients
and interpreted as normal kidney graft biopsies were used
as a calibrator for the molecular analyzes. Urine was
collected in a sterile recipient immediately before each
biopsy, centrifuged and processed as described below.
All patients agreed to participate in the study and signed
an informed consent form. This study was approved by
the Research Ethics Committee of Hospital de Clínicas dePorto Alegre, which is accredited by the National Research
Council of the Brazilian Ministry of Health and registered
at the Office for Human Research Protection- OHR-
PUSDHHS (Institutional Review Board - IRB 00000921).
The study protocol conformed with the ethical guidelines
of the 1975 Helsinki Declaration.
Gene expression analyses
RNA extraction from graft tissue and USC were processed
using the QIAamp® RNA Blood mini kit (QIAGEN Inc.,
Chatsworth, CA, USA), according to the manufacturer’s in-
structions. Total RNA quantifications were accessed by the
Nano’drop® 1000 Spectrophotometer v.3.7 (Thermo Fischer
Scientific, Wilmington, DE, USA) and RNA purity was
evaluated by the ratio of absorbances at the wave lengths
260/280 nM. Total RNA was reverse transcribed to cDNA
using the cDNA High Capacity Kit (Applied Biosystems,
Foster City, CA, USA), according to manufacturer’s instruc-
tions, to a final volume of 20 μL and stored at −20°C.
Real-time polymerase chain reaction (RT-PCR) was
performed in the cDNA from tissue and urine samples by
using the TaqMan Universal PCR Master Mix, composed
by AmpliTaq Gold® DNA polymerase, Amperase UNG,
passive reference (ROX), buffer and dNTP’s (Applied Bio-
systems, Foster City, CA, USA) and specific primers for
KIM-1 mRNA amplification [Applied Biosystems USA
(kidney injury molecule-1 - HAVCR1) ID: Hs00273334_m1]
according to the manufacturer’s instructions. 18 s rRNA
(TaqMan® PDAR) was used as an endogenous control for
sample normalization. FAM (6- carboxyfluorescein) and
VIC dye-labeled TaqMan minor groove binder (MGB)
probes sets were used respectively for HAVCR and 18 s
rRNA, as fluorescent reporter dyes and conjugated at 5’
ends of probes to detect amplification products. The
amount of FAM or VIC fluorescence in each reaction
liberated by the exonuclease degradation of the TaqMan
probe during PCR amplification was measured as a func-
tion of PCR cycle using ABI 7000 Prism (Applied Biosys-
tems, Foster City, CA). RT-PCR was carried out in
duplicates in 96- well plates on 2 μL of cDNA. Thermal
cycling conditions were 50°C for 2 minutes, 60°C for
30 minutes followed by heating to 95°C for 5 minutes and
40 cycles using the temperatures of 94°C for 20 seconds
and 62°C for 60 seconds. Data were collected by using the
ABI PRISM 7000 SDS analytical thermal cycler (Applied
Biosystems, Foster City, CA, USA). The relative quantifi-
cation of target gene expression was performed using the
2–ΔΔCT comparative method where CT (threshold cycle)
value is defined as the point where a statistically signifi-
cant increase in the fluorescence has occurred.
Immunohistochemistry for KIM-1
Immunohistochemistry was performed on formalin-fixed,
paraffin-embedded tissue. Sections were heated in an oven
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in absolute and 95% ethanol, incubated for 5 min in
4.5% H2O2 in methanol to block endogenous peroxidase.
Antigen were retrieved with Antigen Decloaker™ pH 6.0
(Biocare Medical, Walnut Creek, CA, USA) in a pressure
cooker, and blocked with 5% skim milk in PBS for 20 min.
Anti-HAVCR1/KIM-1 polyclonal antibody (LS-B2463,
LifeSpan BioSciences, Seattle, WA, USA) was diluted at
1:600 and incubated overnight at 4°C. After biotin
blockade, slides were incubated with Universal Dako
LSAB® + Kit, with streptavidin-horseradish peroxidase
(Dako, Carpinteria, CA, USA) for 20 min, and devel-
oped with 3.3-diaminobenzidine. All steps included
washing with PBS. Slides were counterstained with Harris
hematoxylin (Merck, Darmstadt, Germany) and placed in
permanent non-aqueous medium (Vector Laboratories,
Burlingame, CA, USA). KIM-1 positivity was defined as a
brown staining of the non-atrophic proximal tubules
according to a semi-quantitative scale: 0 to 3+ (0, no stain-
ing; 1+, weak but entire luminal granular staining; 2+,
entire luminal moderate granular staining; 3+, entire
luminal strong large granular staining [9].
Statistical analyzes
Data are presented as descriptive analyses, medians and
percentiles (P25-75) values. Fisher’s exact test was used
to test associations between categorical variables. Non-
parametric data was analyzed by Kruskal-Wallis test to
compare medians between groups. The correlations
between the levels of gene and protein expression of
KIM-1 in the biopsies were calculated using the Spearman’s
correlation test. The dot-plot representation graphics
show the medians of the relative quantification of gene
expression. All analyzes were performed using the SPSS
(Statistical Package for the Social Sciences) program (ver-
sion 17.0, Chicago, IL). The statistical significance level
was established at P level lower than 0.05.Table 1 Demographics and transplant data
Pathologic diagnosis ATN AR
Number of biopsies 9 43
Age (years) 41 (40–56)1 41 (2
Gender (male/female) 4/5 15/2
Ethnicity (caucasian/non-caucasian) 7/2 39/4
Donor (deceased/living) 8/1 26/1
Donor age (years) 61 (42–63) 47 (4
Induction (Basiliximab/Thymoglobulin) 2/2 11/3
Serum creatinine2,3 (mg/dL) 7.3 (5.1-8.0) 4.3 (
Cold ischemia time (hr) 21 (20–26) 16 (1
Time to biopsy4 (days) 27 (14–84) 13 (9
ATN = acute tubular necrosis; AR = acute rejection; CIN = calcineurin inhibitor nephr
1Median and interquartile range; 2At biopsy; 3Kruskall Wallis (AR > CIN and ATN > ARResults
Patients and transplant demographics are presented in
Table 1. No significant differences were observed among
groups in the parameters of age, gender, ethnicity, use of
antibody induction therapy, donor type, donor age, and
cold ischemia time. Forty-eight (59%) patients received
grafts from deceased donors. A significantly higher serum
creatinine was observed in the ATN group as compared
to the patients classified in the other groups (P <0.05).
The AR group also presented higher serum creatinine
as compared to the CIN group (P <0.05). Time interval
between the transplant surgery and graft biopsy was
higher in the IF/TA group as compared to the ATN
and AR groups (P <0.05).
Tissue protein expression, measured semi-quantitatively,
presented a higher value in the biopsies with a pathological
diagnosis of IF/TA. The median KIM-1 protein expression
in the IF/TA group [1.5 (1.0-2.0)] was significantly higher
than the expression in the ATN [(1.0 (0.0-1.50)], AR [(1.0
(1.0-2.0)] or acute CIN group [0 (0.0 -0.0)] (P = 0.012).
Biopsy staining scores of 2+ and 3+ were present in
50% of the grafts with IF/TA, compared to 11%, 22%
and 25% of those with CIN, ATN and AR respectively.
Tissue mRNA expression was also found to be signifi-
cantly increased in the kidney biopsies classified in the
IF/TA group as compared to all other groups (P <0.05),
as shown in Figure 1A. Expression of the mRNA ob-
tained from the cells of the urinary sediment provided
a much less intense signal of expression. However, its
expression was again significantly higher in the IF/TA
group as compared with the acute CNI group (P <0.05)
(Figure 1B). Importantly, it was found that a more
intense protein expression is paralleled by a higher in-
tensity of the mRNA signal, both in kidney tissue and
USC (Table 2), and also that KIM-1 mRNA expression
both in tissue and USC increased from IF/TA category
I to III (Table 3).CIN IF/TA P
9 20
8–51) 36 (33–54) 39 (30–49) 0.942
8 3/6 10/10 0.644
8/1 18/2 0.495
7 5/4 14/6 0.144
1–51) 47 (33–68) 52 (48–52) 0.248
3/0 8/1 0.573
2.4-5.9) 1.9 (1.7-2.3) 3.3 (2.3-4.5) <0.05
1–22) 19 (12–21) 16 (13–18) <0.05
–49) 31 (18–226) 569 (227–1223) <0.05
otoxicity; IF/TA = interstitial fibrosis and tubular atrophy.
and IF/TA); 4Kruskall Wallis (IF/TA > ATN and AR).
Figure 1 The dot-plot representation graphics showing the medians and distribution of the quantification levels of normalized KIM-1
mRNA (2-ΔΔCT) according to the Banff diagnostic groups. Panel A: kidney tissue. Panel B: urinary sediment cells. ATN = acute tubular necrosis;
AR = acute rejection; CIN = calcineurin inhibitor-induced nephrotoxicity; IFTA = interstitial fibrosis and tubular atrophy.
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mRNA expressions in tissue (r = 0.571; P <0.01) and this
correlation was stronger in the IF/TA group (r = 0.681;
P <0.01). A significant correlation was also found between
protein expression in tissue and mRNA expression in
urinary sediment cells (r = 0.318; P <0.01). The correlation
between mRNA expression in tissue and urinary cell
sediment was also significant (r = 0.348; P <0.01).
Immunohistochemistry slides showing KIM-1 protein
expression in patients with post-transplant IF/TA, ATN,
AR and CIN are shown in the four panels of Figure 2.
No correlations were observed between donor age and
tissue protein expression (r = −0.020; P = 0.869), tissue
mRNA expression (r = −0.023; P = 0.867) and urinary
cells mRNA (r = −0,095; P = 0.440). Also, an inverse non-
significant correlation was observed between cold ischemia
time and KIM-1 tissue protein (r = −0.183; P = 0.228),
tissue mRNA (r = −0.083; P = 0.622) and urinary cells
mRNA (r = −0.188; P = 0.216).
Discussion
KIM-1 molecule is a type 1 trans-membrane glycoprotein
with an intracellular immunoglobulin domain and a highly
glycated mucin extracellular portion [10,11]. The cytoplas-
mic domain is short and has a potentially phosphorilated
site indicating that it might have a role in molecularTable 2 Median and percentiles values (P25–P75) of
KIM-1 mRNA signaling intensity in kidney tissue and
urinary sediment cells according to scores of tissue KIM-1
protein expression
KIM-1 protein tissue Tissue KIM-1 mRNA Urinary KIM-1 mRNA
0 0.02 (0–1.0) 0 (0 – 0)
1+ 4.3 (1.41 – 21.7) 0 (0 – 3.2)
2+ 32.7 (8.45 – 142.4) 0.6 (0 – 3.4)
3+ 1720.9 (885.3 – 1917.4) 5.4 (0 – 8.1)signaling. The ectodomain is clived by a metalloproteinase
and the remaining peptide can be detected in the urine
[12]. It is also known as TIM-1 (T-cell immunoglobulin
mucin-1) and HAVCR-1 (hepatitis A virus cellular
receptor-1) [13]. KIM-1 gene is located at the 5q33.2
human chromosome and its expression is undetectable
in healthy kidneys or in normal urine [14]. However, its
expression increases significantly upon ischemic or
toxic injuries, as in acute renal injury, possibly due to a
protective role in early lesions, and is also increased in
chronic renal failure [5,15].
In the present study we found that, in the renal tissue
of for cause kidney allograft biopsies, mRNA expression
is paralleled by protein expression and also that USC
KIM-1 mRNA transcripts increases in parallel with protein
expression. This represents an increment in the informa-
tion provided in our previous reports in which only the
molecular analyzes were performed [7,8]. Molecular and
protein expressions were more intense in grafts with
the pathological diagnosis of IF/TA suggesting that this
molecule may become a feasible biomarker of kidney
graft fibrosis.
We have previously shown that KIM-1, along with other
fibrosis related genes, have increased mRNA expression of
human kidney grafts undergoing IF/TA [7,16]. However, as
IF/TA does not precisely identifies the etiology of fibrosis itTable 3 Median and percentiles values (P25–P75) of
KIM-1 protein expression in the renal tissue and mRNA
expression levels in kidney tissue and urinary sediment









I 1 (1 – 1) 7.6 (2.2 – 206.7) 1.3 (0.1 – 5.6)
II 1.5 (1 – 2) 29.1 (16.1 – 678.4) 0.1 (0.1 – 3.9)
III 2 (1 – 2) 203.7 (32.0 – 324.0) 5.8 (0.2 – 8.4)
Figure 2 Immunohistochemical staining of KIM-1 in non-atrophic proximal tubules of kidney transplant for-cause biopsies according
to staining intensity. Slide A: interstitial fibrosis and tubular atrophy, 3+; Slide B: acute tubular necrosis, 2+; Slide C; acute rejection, 1+; Slide
D: calcineurin inhibitor nephrotoxicity, very weak staining (original magnification x 400 in A-D).
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TA group there are cases of chronic calcineurin inhibitor
toxicity, chronic alloimune injury and advanced polioma
virus nephropathy. In this scenario we believe that KIM-1
is overexpressed in grafts undergoing fibrosis due to differ-
ent causes. Donor age could be a confounding variable in
evaluating KIM-1 expression. In the present work donor
age was not significantly different between diagnostic
groups and we did not find protein or molecular KIM-1 ex-
pressions to be correlated with donor age. Other donor re-
lated variables, such as living compared to deceased
donors, were not possible to evaluate due to the restricted
number of living donor transplants in our series. We also
found a considerable variability in the mRNA expressions
across the diagnostic groups. It is possible that refinements
in the diagnosis of the different cause of fibrosis may pro-
vide more reproducible results.
Experimentally, increased production of Kim-1 has been
demonstrated predominantly in the S3 portion of the prox-
imal tubule in response to a variety of injuries or as a result
of dedifferentiation of the tubular epithelia [17,18]. In native
kidneys with fibrotic processes the increased expression of
KIM-1 was recently reviewed by Lim et al. [19]. It has being
demonstrated that this molecule is significantly expressed
in the apical site of dilated tubules of the fibrotic areas in a
variety of renal disorders and that KIM-1 expression was
associated to the glomerular macrophage influx. Histo-
chemistry double immunostaining studies revealed that
KIM-1 is present in these macrophages infiltrating areas,
accompanied by fibrosis and dedifferentiated tubular cells[19]. In an elegant set of experiments, Humphreys et al.
[20] proposed a novel role for chronic KIM-1 expression in
the pathogenesis of renal fibrosis through activation of the
innate immune system and leukocyte recruitment. They
suggested that persistent KIM-1 expression is maladaptive
through chronic uptake of cell toxic components of the
tubular lumen, promoting chronic inflammation and ultim-
ately renal fibrosis, making KIM-1 a potential novel thera-
peutic target in fibrotic kidney diseases.
In humans it has being shown that KIM-1 is expressed
predominantly in the proximal apical membrane of nec-
rotic and apoptotic cells of the tubular lumen [21].
Augmented KIM-1 expression was initially described in
biopsies samples of patients with ATN were it was also
found to be increased in the urine as measured by ELISA
[11]. Latter it was found, in a variety of renal diseases, that
KIM-1 was primarily expressed at the luminal side of
dedifferentiated proximal tubules, in areas with fibrosis
and inflammation [22]. Also in humans KIM-1 expression
has being found to be increased in other clinical settings
such as urate nephropathy and renal cell carcinoma [19].
KIM-1 has not been extensively studied in human renal
transplantation [23]. In the early studies by van Timmeren
et al. [24] it was found that urinary KIM-1 is an independ-
ent predictor of long-term graft loss and it has also being
reported, by Jin et al. [25], as predictive of the develop-
ment of later acute rejection when measured in the blood
at day 1 post-transplantation. Zhang et al. [9] reported
that KIM-1 tissue staining is a sensitive and specific
marker of early proximal tubular injury and correlates
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mRNA obtained from kidney grafts before implantation
correlates inversely with kidney function at procurement
and directly with the degree of interstitial fibrosis [26]. Fi-
nally, KIM-1 mRNA measurement in the urine has been
shown to be predictive of declining renal function and late
graft loss independently of acute rejection [27]. Taken to-
gether these reports are supportive of our present data
showing, as reported in other settings, that in renal trans-
plantation KIM-1 is involved in graft fibrosis processes.
Conclusions
In the present study the gene expression of KIM-1 was
paralleled by protein expression in the renal tissue of for
cause kidney allograft biopsies. Messenger RNA tran-
scripts of KIM-1 in urine also increased in parallel with
protein expression. Interestingly, molecular and protein
expressions were higher in grafts with interstitial fibrosis
and tubular atrophy suggesting that KIM-1 represents a
potential biomarker of injuries that can lead to kidney
allograft fibrosis.
Currently the pathological diagnosis is the gold-standard
for the evaluation of the aggressions to the kidney allograft.
However, it is highly recognized that there is a need for
the development of accurate non-invasive biomarkers
to uncover, prognosticate and guide therapy without
the need of invasive and risky methods. Messenger
RNA profiling in the urine might have the advantage of
detecting injury before the initiation of scarring. We
believe that improvements on mRNA biomarker research,
perhaps along with other platforms, will be the way for
providing earlier and better interventions and thus leading
to improvement in renal graft survival.
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